معرفی
Matthew W. VanBrocklin is an Associate Professor in the Department of Surgery at the University of Utah, serving as an Investigator at the Huntsman Cancer Institute and member of both the Cell Response and Regulation Program and Melanoma Disease Center. His research program focuses on three key areas: oncolytic virotherapy, immune checkpoint ligand investigation, and single vector CRISPR/HDR technology.
- Department of Surgery (General Surgery)
- Oncological Sciences (Adjunct)
VanBrocklin's lab develops oncolytic Picornaviruses that exploit tumor cell vulnerabilities through innate immune pathway loss. His team investigates B7-H3 (CD276) as an emerging immunotherapeutic target, aiming to identify its receptor and develop blocking antibodies. The CRISPR/HDR platform achieves 23% repair efficiency in vitro, with ongoing in vivo evaluations for genetic disorders like cystic fibrosis and muscular dystrophy.
Recent publications highlight his work on:
- miR211-5p transdermal delivery for BRAFV600E+ nevi stabilization (2025)
- AKT/mTOR pathway suppression in melanoma (2024)
- BRAFV600E microRNA mechanisms (2021)
- Aspirin's protective effects against UVB damage (2020)
